List view / Grid view
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
Researchers are exploring the potential use of HDAC inhibitors, a group of drugs known for their capability to impede tumour cell division, to reduce the pain and damage associated with sickle cell disease. The drugs have shown initial evidence of reactivating the gene responsible for producing foetal haemoglobin, which cannot…
Researchers have found that new sickle cell disease gene therapies depend on choosing the right laboratory mice.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
Researchers have developed a novel organ-on-a-chip model of sickle cell disease to improve personalised medicine.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
A study has used new synthetic lipids to deliver CRISPR gene editing tools into cells with up to 90 percent efficiency.
